Overview


According to FutureWise analysis the market for Cervical Intraepithelial Neoplasia Drugs in 2023 is US$ 0.59 billion, and is expected to reach US$ 0.98 billion by 2031 at a CAGR of 6.50%.

Cervical intraepithelial neoplasia (CIN) is a condition in which abnormal cells proliferate inside the cervix. It can be caused by some types of the human papillomavirus (HPV), as well as other environmental factors, and it can occasionally progress to cervical cancer precursors. Cervical intraepithelial neoplasia is more prevalent than cervical cancer. The cervix is the lower portion of the uterus that enters the vaginal canal. The cervix dilates during childbirth to allow the foetus to pass through. In cervical intraepithelial neoplasia, the abnormal cells aren't cancerous. If not watched or treated in certain circumstances that necessitate therapy, it might develop into precancers or cancer. Cervical dysplasia is another name for this disorder.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Cervical Intraepithelial Neoplasia Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Cervical Intraepithelial Neoplasia Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Boehringer Ingelheim International GmbH.
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • MerckCo., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Biocon
  • Evado Pty. Ltd.
  • Amgen Inc.
  • Eli Lilly and Company
  • Allergan
  • Hetero
  • Abbott
  • QIAGEN
  • Danaher

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Disease Type

  • Cervical Intraepithelial Neoplasia 1
  • Cervical Intraepithelial Neoplasia 2
  • Cervical Intraepithelial Neoplasia 3

By Treatment

  • Surgery
  • Hysterectomy
  • Cone biopsy
  • Loop electrosurgical excision procedure (LEEP)
  • Laser therapy
  • Cryosurgery
  • Medication
  • Avastin
  • Bevacizumb
  • Blemocin
  • Blenoxane
  • Others

By Indication

  • Pre-malignant Lesions
  • Early Invasive Stage
  • Advanced Invasive Stage

By Dosage Form

  • Solution
  • Powder
  • Injection
  • Cream
  • Others

By Route of Administration

  • Intravenous
  • Topical
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Cervical Intraepithelial Neoplasia Drugs Market By Disease Type, By Treatment, By Indication, By Dosage Form, By Route of Administration, By End-Users, By End Users and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Cervical Intraepithelial Neoplasia Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Cervical Intraepithelial Neoplasia Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Cervical Intraepithelial Neoplasia Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Cervical Intraepithelial Neoplasia Drugs Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cervical Intraepithelial Neoplasia 1
        2. Cervical Intraepithelial Neoplasia 2
        3. Cervical Intraepithelial Neoplasia 3

  • 8.   Cervical Intraepithelial Neoplasia Drugs Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Surgery
        2. Hysterectomy
        3. Cone biopsy
        4. Loop electrosurgical excision procedure (LEEP)
        5. Laser therapy
        6. Cryosurgery
        7. Medication
        8. Avastin
        9. Bevacizumb
        10. Blemocin
        11. Blenoxane
        12. Others

  • 9.   Cervical Intraepithelial Neoplasia Drugs Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pre-malignant Lesions
        2. Early Invasive Stage
        3. Advanced Invasive Stage

  • 10.   Cervical Intraepithelial Neoplasia Drugs Market, By Dosage Form Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Solution
        2. Powder
        3. Injection
        4. Cream
        5. Others

  • 11.   Cervical Intraepithelial Neoplasia Drugs Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Intravenous
        2. Topical
        3. Others

  • 12.   Cervical Intraepithelial Neoplasia Drugs Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 13.   Cervical Intraepithelial Neoplasia Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 14.   North America Cervical Intraepithelial Neoplasia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 15.   Latin America Cervical Intraepithelial Neoplasia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 16.   Europe Cervical Intraepithelial Neoplasia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 17.   Asia Pacific Cervical Intraepithelial Neoplasia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 18.   Middle East and Africa Cervical Intraepithelial Neoplasia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 19.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 20.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer Inc.
                1.1. Company Overview
                1.2. Product Portfolio
                1.3. SWOT Analysis
                1.4. Financial Overview
                1.5. Strategic Overview
        2. GlaxoSmithKline plc
                2.1. Company Overview
                2.2. Product Portfolio
                2.3. SWOT Analysis
                2.4. Financial Overview
                2.5. Strategic Overview
        3. Novartis AG
                3.1. Company Overview
                3.2. Product Portfolio
                3.3. SWOT Analysis
                3.4. Financial Overview
                3.5. Strategic Overview
        4. Mylan N.V.
                4.1. Company Overview
                4.2. Product Portfolio
                4.3. SWOT Analysis
                4.4. Financial Overview
                4.5. Strategic Overview
        5. Teva Pharmaceutical Industries Ltd.
                5.1. Company Overview
                5.2. Product Portfolio
                5.3. SWOT Analysis
                5.4. Financial Overview
                5.5. Strategic Overview          
        6. Sanofi
                6.1. Company Overview
                6.2. Product Portfolio
                6.3. SWOT Analysis
                6.4. Financial Overview
                6.5. Strategic Overview      
        7. Boehringer Ingelheim International GmbH.
                7.1. Company Overview
                7.2. Product Portfolio
                7.3. SWOT Analysis
                7.4. Financial Overview
                7.5. Strategic Overview
        8. AstraZeneca
                8.1. Company Overview
                8.2. Product Portfolio
                8.3. SWOT Analysis
                8.4. Financial Overview
                8.5. Strategic Overview
        9. Johnson & Johnson Private Limited
                9.1. Company Overview
                9.2. Product Portfolio
                9.3. SWOT Analysis
                9.4. Financial Overview
                9.5. Strategic Overview
        10. Merck & Co., Inc.
                10.1. Company Overview
                10.2. Product Portfolio
                10.3. SWOT Analysis
                10.4. Financial Overview
                10.5. Strategic Overview
        11. F. Hoffmann-La Roche Ltd.
                 11.1. Company Overview
                 11.2. Product Portfolio
                 11.3. SWOT Analysis
                 11.4. Financial Overview
                 11.5. Strategic Overview
        12. Bristol-Myers Squibb Company
                 12.1. Company Overview
                 12.2. Product Portfolio
                 12.3. SWOT Analysis
                 12.4. Financial Overview
                12.5. Strategic Overview
        13. Biocon
                 13.1. Company Overview
                 13.2. Product Portfolio
                 13.3. SWOT Analysis
                 13.4. Financial Overview
                 13.5. Strategic Overview
        14. Evado Pty. Ltd.
                 14.1. Company Overview
                 14.2. Product Portfolio
                 14.3. SWOT Analysis
                 14.4. Financial Overview
                 14.5. Strategic Overview
        15. Amgen Inc.
                 15.1. Company Overview
                 15.2. Product Portfolio
                 15.3. SWOT Analysis
                 15.4. Financial Overview
                 15.5. Strategic Overview          
        16. Eli Lilly and Company
                 16.1. Company Overview
                 16.2. Product Portfolio
                 16.3. SWOT Analysis
                 16.4. Financial Overview
                 16.5. Strategic Overview      
        17. Allergan
                 17.1. Company Overview
                 17.2. Product Portfolio
                 17.3. SWOT Analysis
                 17.4. Financial Overview
                 17.5. Strategic Overview
        18. Hetero
                 18.1. Company Overview
                 18.2. Product Portfolio
                 18.3. SWOT Analysis
                 18.4. Financial Overview
                 18.5. Strategic Overview
        19. Abbott
                 19.1. Company Overview
                 19.2. Product Portfolio
                 19.3. SWOT Analysis
                 19.4. Financial Overview
                 19.5. Strategic Overview
        20. QIAGEN
                 20.1. Company Overview
                 20.2. Product Portfolio
                 20.3. SWOT Analysis
                 20.4. Financial Overview
                 20.5. Strategic Overview
        21. Danaher
                 21.1. Company Overview
                 21.2. Product Portfolio
                 21.3. SWOT Analysis
                 21.4. Financial Overview
                 21.5. Strategic Overview

  • 21.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 22.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients